Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 731 KiB)
Zeuschner, P.; Hölters, S.; Stöckle, M.; Seliger, B.; Mueller, A.; Bachmann, H.S.; Grünwald, V.; Christoph, D.C.; Stenzl, A.; Grimm, M.-O.; Brüning, F.; Goebell, P.J.; Augustin, M.; Roos, F.; Harde, J.; Benz-Rüd, I.; Staehler, M.; Junker, K. Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers 2021, 13, 2594. https://doi.org/10.3390/cancers13112594
Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K. Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers. 2021; 13(11):2594. https://doi.org/10.3390/cancers13112594
Chicago/Turabian StyleZeuschner, Philip, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S. Bachmann, Viktor Grünwald, Daniel C. Christoph, Arnulf Stenzl, Marc-Oliver Grimm, Fabian Brüning, Peter J. Goebell, Marinela Augustin, Frederik Roos, Johanna Harde, Iris Benz-Rüd, Michael Staehler, and Kerstin Junker. 2021. "Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)" Cancers 13, no. 11: 2594. https://doi.org/10.3390/cancers13112594